Evidence map›Paper›PMID 37405617›Full record

ArticleJournal of patient-reported outcomes2023

Development and content validity assessment of the Dry Eye Disease Questionnaire in patients with dry eye disease, meibomian gland dysfunction, and Sjögren's syndrome dry eye disease.

Brigitte Sloesen, Alyson Young, Katie Forde, Nicola Hodson, Sarah Bentley, Oonagh Walsh, Christel Naujoks, Paul O'Brien, Garima Sharma

Open access · goldAbstract read
In one paragraph

Article in Journal of patient-reported outcomes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Brigitte SloesenNovartis Pharma AG, Basel, Switzerland. brigitte.sloesen@novartis.com.
Alyson YoungAdelphi Values, Patient-Centered Outcomes, Cheshire, UK.
Katie FordeAdelphi Values, Patient-Centered Outcomes, Cheshire, UK.
Nicola HodsonAdelphi Values, Patient-Centered Outcomes, Cheshire, UK.
Sarah BentleyAdelphi Values, Patient-Centered Outcomes, Cheshire, UK.
Oonagh WalshNovartis Pharma AG, Basel, Switzerland.
Christel NaujoksNovartis Pharma AG, Basel, Switzerland.
Paul O'BrienNovartis Ireland Limited, Dublin, Ireland.
Garima SharmaNovartis Healthcare Private Limited, Hyderabad, India.
Adelphi Group (United Kingdom) · GBNovartis (Switzerland) · CHNovartis (India) · INNovartis (Ireland) · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDry eye disease (DED), Meibomian gland dysfunction (MGD), and Sjögren's syndrome dry eye disease (SS-DED) are eye dryness conditions that show significant overlap in various symptoms of ocular discomfort. The aim of this study was to qualitatively explore the patient experience and evaluate content validity of the newly developed Dry Eye Disease Questionnaire (DED-Q).

methodsSemi-structured interviews were conducted with 61 US adults who reported experiencing ocular symptoms due to their physician-confirmed primary diagnosis of DED (n = 21), MGD (n = 20), or SS-DED (n = 20). The open-ended concept-elicitation phase was followed by cognitive debriefing (CD) of the DED-Q to evaluate participants' understanding and relevance of the instructions, items, response options, and recall periods. Interviews were also conducted with eight specialist healthcare professionals to assess clinical relevance of the concepts included. Verbatim interview transcripts were analyzed using thematic analysis in ATLAS.ti v8 software.

resultsA total of 29 symptoms and 14 impacts on quality of life were reported across participant interviews. Primary ocular symptoms reported included eye dryness (n = 61/61; 100%), eye irritation (n = 55/61; 90%), eye itch (n = 54/61; 89%), burning sensation (n = 52/61; 85%), and foreign body sensation (n = 51/61; 84%). The most impacted aspects of daily life were using digital screens (n = 46/61; 75%), driving (n = 45/61; 74%), working (n = 39/61; 64%), and reading (n = 37/61; 61%). CD findings showed most participants had good understanding of DED-Q items and confirmed most concepts were relevant to the lived experience of their condition. Aside from few minor changes to the items and examples to facilitate more accurate interpretation, the proposed instruction wording was modified for various symptom and impact modules to encourage participants to focus only on dry eye vision problems.

conclusionsThis research identified multiple prevalent symptoms and impacts of DED, MGD, and SS-DED, most of which were similar across the conditions. The DED-Q was confirmed to be a content-valid PRO measure suitable for use in clinical studies to assess the patient experience of DED, MGD, and SS-DED. Future work will focus on evaluating the psychometric properties of the DED-Q for use as an efficacy endpoint in clinical trials.

Indexed as

Dry Eye SyndromesMeibomian Gland DysfunctionSjogren's SyndromeAdultHumansQuality of LifeSurveys and QuestionnairesCognitive debriefingConcept elicitationContent validityDry eye diseaseMeibomian gland dysfunctionPatient-reported outcomeSjogren’s syndrome dry eye

Identifiers

PMID37405617
PMCPMC10323053
OpenAlexW4383186655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.